RespireRx Pharmaceuticals Inc.
RSPI
$0.0021
$0.0011110.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.10M | 1.10M | 945.90K | 1.15M | 1.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.41M | 1.47M | 1.35M | 1.58M | 1.87M |
| Operating Income | -1.41M | -1.47M | -1.35M | -1.58M | -1.87M |
| Income Before Tax | -1.80M | -1.87M | -1.67M | -2.10M | -2.59M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.80 | -1.87 | -1.67 | -2.10 | -2.59 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.80M | -1.87M | -1.67M | -2.10M | -2.59M |
| EBIT | -1.41M | -1.47M | -1.35M | -1.58M | -1.87M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.01 | -0.03 | -0.03 | -0.04 | -0.04 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| EPS Diluted | -0.01 | -0.03 | -0.03 | -0.04 | -0.04 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| Average Basic Shares Outstanding | 694.97M | 546.50M | 484.37M | 445.08M | 425.36M |
| Average Diluted Shares Outstanding | 694.97M | 546.50M | 484.37M | 445.08M | 425.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |